trending Market Intelligence /marketintelligence/en/news-insights/trending/vh4u4jzkc0sdkvjvrly-wq2 content esgSubNav
In This List

CytoDyn adds Argonne Capital president/CEO to board

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


CytoDyn adds Argonne Capital president/CEO to board

CytoDyn Inc. appointed Michael Klump to its board as a director.

Klump, who is also a significant CytoDyn investor, is the founder, president and CEO of private equity firm Argonne Capital Group LLC.

Vancouver, Wash.-based CytoDyn develops humanized monoclonal antibodies to treat and prevent HIV infection. Its lead drug candidate is PRO 140, a humanized immunoglobulin G4, or igG4, monoclonal antibody that blocks the cellular receptor implicated in HIV infection, tumor metastasis and immune signaling.